- Base-Edited HSPCs Are Shielded from Targeted CD33 Therapy but Preserve CD33 Expression
- Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases
- Cimeio Therapeutics Presents Data for its CD45 Universal Heme ADC at ASH
- Cimeio Therapeutics Announces Poster Presentations at ASH 2023
- Cimeio Therapeutics Announces Research Collaboration With the University of Pennsylvania
No comments to show.